<SEC-DOCUMENT>0001558370-20-001887.txt : 20200302
<SEC-HEADER>0001558370-20-001887.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302161101
ACCESSION NUMBER:		0001558370-20-001887
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200302
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		20676903

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>omer-20200302x8kbf733aa.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.5.7293.39921 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/2/2020 9:10:41 PM -->
      <!-- iXBRL Library version: 1.0.7293.39928 -->
      <!-- iXBRL Service Job ID: 25c7dfd6-7ea7-4326-a892-2808634a922a -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:omer="http://www.omeros.com/20200302" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityCentralIndexKey" id="Tc_idTC6a8o90Gq0KOQiBbASA_2_1">0001285819</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:AmendmentFlag" id="Tc_ZndKK9OOu06C-qLVcWgQjg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="omer-20200302.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:DocumentType" id="Narr_XqELUp-uWkO0PMKgbGSOqQ">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_OOQQPSpHsEK7l5Kt6WltyQ"><b style="font-weight:bold;">March 2, 2020</b></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:24pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityRegistrantName" id="Narr_u8laeVwiukyafDAUDwlJHg">OMEROS CORPORATION</ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_439b5711_d9b7_412e_9fb8_26d33a59c6a2"></a><a id="Tc_kWzyY7Tr-kabW2m2qJ8dDg_1_0"></a><a id="Tc_rjtXHNfsu0iuLvSJX6d4GQ_1_1"></a><a id="Tc_MByuhYM3oUmMNFB84XbdJA_1_2"></a><a id="Tc_V42900dYmEGyzi9LCUZpuA_3_0"></a><a id="Tc_8U7NV5C0QEmmyi8oYI235g_4_0"></a><a id="Tc_7X4v1_CcdkqR-_Qplx6-yg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_F9Fk0Q0AwkS2WJAjtU4zwA_0_0"><b style="font-weight:bold;">Washington</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityFileNumber" id="Tc_zuV9QnQJRk-oCQea20Om0w_0_1"><b style="font-weight:bold;">001-34475</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityTaxIdentificationNumber" id="Tc_1Nkl5EqvIECtuJgEckbm6w_0_2"><b style="font-weight:bold;">91-1663741</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Incorporation)</b></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityAddressAddressLine1" id="Narr_X9A5RlJEFEumFiHP74irEg"><b style="font-weight:bold;">201 Elliott Avenue West</b></ix:nonNumeric><br /><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityAddressCityOrTown" id="Narr_yFPrEcQGB0qeo_j3yVf1fQ"><b style="font-weight:bold;">Seattle</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityAddressStateOrProvince" id="Narr_ClpitDxRl0G0RZ_yF19oig"><b style="font-weight:bold;">WA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt 1pt 0pt 2pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:EntityAddressPostalZipCode" id="Tc_nfV4K-gFWE6KWDt9OyqUvQ_3_2"><b style="font-weight:bold;">98119</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt 1pt 0pt 2pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s Telephone Number, Including Area Code: (</b><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:CityAreaCode" id="Narr_g3U0AO9cekSyd8GjtTEf0A"><b style="font-weight:bold;">206</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:LocalPhoneNumber" id="Narr_GvgO6AlSdU2gOmyXw64f0w"><b style="font-weight:bold;">676-5000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_qCbkWREyI0mSMtvTW5ssuw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_LV9-E1N6GEyRNK0RI14wJw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_XqOFZg5EG0ikHG3G3H3Xlg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_x_t0pYSpR0GfcDsyZWdzKQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Securities Registered Pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_fc824eb1_f8ea_4b0e_83a7_c681efbb8280"></a><a id="Tc_IHllydLvEEaaHcU1ioSq9g_0_0"></a><a id="Tc_y-4_b-TsGUKdKU7fMvUWNA_0_1"></a><a id="Tc_0bdDPpRxCUiAdy07aVM0Fg_0_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:38.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:23.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:37.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:38.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:Security12bTitle" id="Tc_G6B-50qyA0CTT1drdkKzog_1_0">Common stock, $0.01 par value per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:23.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" name="dei:TradingSymbol" id="Tc_jv15teW0-UObMy9nhg1yYg_1_1">OMER</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:37.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_KmonDcx4AkWaBHMm78UrLA_1_2">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).<span style="display:inline-block;width:0.75pt;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_zMvvgleXg0-oI5kyddtWIQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.02 Results of Operations and Financial Condition.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2020, Omeros Corporation issued a press release announcing financial results for the three&#160;months and year ended December 31, 2019.&#160;A copy of such press release is furnished herewith as Exhibit&#160;99.1 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information in this Current Report on Form&#160;8-K, including the exhibit hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section&#160;or Sections 11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01 Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:87.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="ex-99d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release, dated March 2, 2020, pertaining to Omeros Corporation&#8217;s financial results for the three months and year ended December 31, 2019.</span></a></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OMEROS CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Date: March 2, 2020</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/ Gregory A. Demopulos</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gregory A. Demopulos, M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">President, Chief Executive Officer and</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chairman of the Board of Directors</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 3/2/2020 2:10:28 PM-->
<html>
	<head>
		<title>
			omer_EX99_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="ex-99d1g001.jpg" style="width: 1.5in; height: 1.010417in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">&#x2013;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> Conference Call Today at 4:30 p.m. ET </font><font style="display:inline;font-weight:bold;">&#x2013;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">SEATTLE, WA &#x2013; March 2, 2020 &#x2013; </font><font style="display:inline;font-size:11pt;">Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2019, which include:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<a name="_Hlk32911581"></a><font style="display:inline;font-size:11pt;">4Q 2019 OMIDRIA</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> revenues were $33.4 million, Omeros&#x2019; highest revenue quarter to date and representing another quarter of double-digit growth of 12 percent compared to 3Q 2019. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Full year 2019 OMIDRIA revenues were $111.8 million, a 274 percent increase from the prior year. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Net loss in 4Q 2019 was $29.2 million, or $0.58 per share. Net loss for the full year 2019 was $84.5 million, or $1.71 per share. Non-cash expenses for the fourth quarter and the full year of 2019 were $6.3 million, or $0.12 per share, and $24.8 million, or $0.50 per share, respectively. Included in both 4Q and full year net loss is $12.6 million, or $0.25 per share, in connection with Omeros&#x2019; election to accelerate the manufacturing schedule for a one-time set of five narsoplimab process validation and commercial lots. These lots were successfully manufactured, provide data to satisfy the BLA process validation requirements, and can be used for commercial sales following approval.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">At December 31, 2019, the company had cash, cash equivalents and short-term investments available for operations of $60.8 million.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Data from the narsoplimab pivotal registration trial met the FDA-agreed primary efficacy endpoint, with complete response rates of 54 percent (p&lt;0.0001) in all patients receiving at least one dose of narsoplimab and 65 percent (p&lt;0.0001) in all patients receiving at least the protocol-specified four weeks of dosing, well surpassing the FDA-agreed threshold for efficacy of 15 percent</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">On the secondary endpoint of 100-day survival, 68 percent of all patients receiving at least one dose of narsoplimab achieved 100-day survival, with 83 percent of patients receiving at least the protocol-specified four weeks of dosing and 93 percent of responders achieving the endpoint. Experts familiar with the pivotal trial data would expect a 100-day survival rate of less than 20 percent in this population.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&#x201C;2019 was a year of tremendous accomplishment for Omeros,&#x201D; stated Gregory A. Demopulos, M.D., Omeros&#x2019; chairman and chief executive officer. &#x201C;Our pivotal trial in HSCT-TMA generated data that substantially surpass FDA&#x2019;s agreed threshold for efficacy and enabled submission of the first sections of our rolling BLA, OMIDRIA delivered record annual sales of $112 million, and we discovered a cancer immunity axis controlled by GPR174, a target that we control and expect could change the immuno-oncology landscape. And 2020 is shaping up to be an even better year. We are on track to complete submission of the narsoplimab BLA for HSCT-TMA and look forward to FDA&#x2019;s review and approval as we move the drug toward two additional indications in IgA nephropathy and aHUS. We expect that 2020 will also bring continued growth in OMIDRIA sales, further clinical development of our OMS527 addiction program, a Phase 1 trial for our MASP-3 inhibitor OMS906, and ongoing progress with our MASP-2 small-molecule inhibitor and next-generation antibody as well as our GPR174 antagonists, driving them toward the clinic. We&#x2019;ve built a top-tier group of first-in-kind </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;font-size:11pt;">assets, are delivering on their promise, and expect that they will significantly improve the lives of patients and their families.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Fourth Quarter and Recent Developments</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Recent developments regarding narsoplimab, Omeros&#x2019; lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) in Phase 3 clinical programs for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), Immunoglobulin A (IgA) nephropathy, and atypical hemolytic uremic syndrome (aHUS), include the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Omeros recently announced positive data across primary and secondary endpoints in its pivotal trial of narsoplimab in HSCT-TMA patients.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-size:11pt;">The primary endpoint is a set of rigorous response criteria requiring improvements in HSCT-TMA laboratory markers and improvement in clinical status. The FDA-agreed threshold for the efficacy primary endpoint in the very sick patient population treated in this trial is a response rate of 15 percent. Across all patients receiving at least one dose of narsoplimab, 54 percent (p&lt;0.0001) were complete responders; in patients receiving at least the protocol-specified four weeks of narsoplimab treatment, the complete response rate was 65 percent (p&lt;0.0001).</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:5pt 0pt 6pt;">
				<font style="margin:5pt 0pt 6pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:5pt 0pt 6pt;">
			<font style="display:inline;font-size:11pt;">The secondary endpoints include survival rates and change from baseline in laboratory markers. The 100-day survival rate was 68 percent in all patients who received at least one dose of narsoplimab, 83 percent in patients who received at least the protocol-specified 4 weeks of narsoplimab treatment, and 93 percent in responders. Experts familiar with the pivotal trial data would expect a 100-day survival rate of less than 20 percent in this population. Across all patients, statistically significant improvement was seen in platelet count and LDH and haptoglobin levels (p&lt;0.01 for each marker).</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">The most commonly reported adverse events in the trial were diarrhea, nausea, vomiting, hypokalemia, neutropenia and fever &#x2013; all common in stem-cell transplant patients. Six deaths also occurred during the trial and were due to sepsis, progression of the underlying disease and graft-versus-host disease. All of these are common causes of death in this patient population.&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">In February 2020, Omeros met with FDA to discuss the chemistry, manufacturing and controls aspects of the Biologics License Application (BLA) for narsoplimab in HSCT-TMA. At the meeting, FDA requested near-term manufacturing dates for narsoplimab so that FDA&#x2019;s pre-approval inspections could be scheduled. FDA and Omeros also reached agreement on requirements for stability data and release assays for the BLA</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Data from the narsoplimab pivotal trial in HSCT-TMA were presented and discussed by a panel of international experts in hematopoietic stem-cell transplantation at a recent continuing medical education symposium held at the Transplant and Cellular Therapy Conference in Orlando. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Omeros initiated a collaboration with myTomorrows, a global health technology company, to broaden its expanded access program to support international availability of narsoplimab to eligible patients who have no other treatment options. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">The ARTEMIS-IGAN Phase 3 clinical trial for narsoplimab in IgA nephropathy is ongoing at 91 sites in the U.S. and internationally, with additional sites coming on line. Data readout is expected next year. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Multiple manuscripts directed to narsoplimab in IgA nephropathy have been accepted for publication or are under review by peer-reviewed journals. Most recently, a review article entitled &#x201C;MASP-2 Inhibition as Potential Strategy for IgA Nephropathy Management&#x201D; authored by Drs. Jonathan Barratt of University of Leicester and Richard Lafayette of Stanford University was accepted for publication in the journal </font><font style="display:inline;font-style:italic;font-size:11pt;">Drugs of the Future</font><font style="display:inline;font-size:11pt;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Recent developments regarding OMIDRIA include the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act was introduced in the both the U.S. House of Representatives and the U.S. Senate during the fourth quarter. The proposed legislation has strong bipartisan backing in both chambers of Congress and is supported by a diverse group of grassroots organizations. If passed, the legislation would mandate separate payment by Centers for Medicare and Medicaid Services (CMS) for a period of five years for non-opioid pain treatments used during surgery, like OMIDRIA. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">The new product-specific permanent J-code for OMIDRIA became effective on October 1, 2019. J-codes standardize the submission and payment of insurance claims across Medicare, Medicare Advantage, Medicaid and commercial insurance plans.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Updates regarding Omeros&#x2019; other development programs and platforms include the following: <br><br></font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Omeros&#x2019; MASP-3 inhibitor OMS906 is on track for clinical entry in June of this year. Initially targeting paroxysmal nocturnal hemoglobinuria (PNH), OMS906 is expected to allow monthly subcutaneous dosing.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">Following positive results from the Phase 1 study, Omeros is planning for a Phase 2 trial of its phosphodiesterase 7 inhibitor OMS527 in nicotine addiction.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Courier New;border-top:1pt none #D9D9D9;font-size:11pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">In the fourth quarter of 2019, Omeros presented new data on its GPR174 immuno-oncology program at international medical congresses. Data from human </font><font style="display:inline;font-style:italic;font-size:11pt;">ex vivo</font><font style="display:inline;font-size:11pt;"> studies demonstrate that GPR174 inhibition results in downregulation of checkpoint and tumor-promoting factors. In addition, data from animal models reveal enhanced anti-tumor immune responses in GPR174-deficient mice and synergism between adenosine receptor antagonists and GPR174 antagonists in promoting interleukin-2 (IL-2) and interferon-&#x3B3; (IFN-&#x3B3;) production from human T cells. Omeros discovered a cancer-immunity axis controlled by GPR174 and is building an exclusive intellectual property position directed to modulation of GPR174 for the treatment of cancer.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<a name="_Hlk506276822"></a><font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">In December 2019, Omeros raised $54.2 million in net proceeds&nbsp;in an underwritten offering of common stock.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Financial Results</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-style:italic;font-size:11pt;text-decoration:underline;">Fourth Quarter 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For the quarter ended December 31, 2019, revenues were $33.4 million, all relating to sales of OMIDRIA. This compares to OMIDRIA revenue of $22.0 million for the same period in 2018. On a sequential quarter-over-quarter basis, OMIDRIA revenue increased by $3.6 million or 12 percent. The increases from the prior year and from the prior quarter are primarily due to a growing number of purchasing accounts as well as deeper penetration within accounts across hospitals, ambulatory surgery centers and government payers. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Total operating costs and expenses for the quarter ended December 31, 2019 were $57.1 million compared to $40.5 million for the comparable period in 2018 and $41.0 million in the preceding quarter.&nbsp;&nbsp;The increase in both cases primarily reflects $12.6 million of expenses incurred ahead of schedule due to Omeros&#x2019; election to accelerate the manufacturing schedule for a one-time set of five narsoplimab process validation and commercial lots. These lots were successfully manufactured, provide data to satisfy the BLA process validation requirements, and can be used for commercial sales following approval. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For the three months ended December 31, 2019, Omeros reported a net loss of $29.2 million or $0.58 per share, which included non-cash expenses of $6.3 million ($0.12 per share) and the aforementioned manufacturing expenses of $12.6 </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">million ($0.25 per share). This compares to the prior year&#x2019;s fourth quarter when Omeros reported a net loss of $23.5 million, or $0.48 per share, which included non-cash expenses of $4.9 million ($0.10 per share).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-style:italic;font-size:11pt;text-decoration:underline;">Full Year 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Revenues for the full year 2019 were $111.8 million compared to $29.9 million for full year 2018.&nbsp;&nbsp;The significant increase year-over-year is primarily due to the status of pass-through reimbursement. During the period January 1, 2018 to September 30, 2018, OMIDRIA was not reimbursed separately under Medicare Part B. This had a significant negative impact on revenues during 2018. Following reinstatement of pass-through reimbursement on October 1, 2018, OMIDRIA revenues quickly returned to and exceeded previous levels.&nbsp; </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For the year ending December 31, 2019, total costs and expenses were $175.2 million compared to $142.1 million in the prior year. The increase for the current year compared to the prior year is due primarily to the additional narsoplimab manufacturing, an increase in spending on preclinical research and development in our OMS906 program and the resumption of OMIDRIA marketing activities following reinstatement of pass-through reimbursement on October 1, 2018.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">At December 31, 2019, the company had cash, cash equivalents and short-term investments available for operations of $60.8 million and an accounts receivable balance of $35.2 million. The company also has an accounts receivable-based line of credit which permits borrowing up to the lesser of $50.0 million and 85 percent of eligible accounts receivable, subject to applicable reserves. We have not borrowed under this facility.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Conference Call Details</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Omeros&#x2019; management will host a conference call to discuss the financial results and to provide an update on business activities. The call will be held today at 4:30 p.m. Pacific Time; 1:30 p.m. Eastern Time. To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 4870947. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 4870947. &nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">To access the live or subsequently archived webcast of the conference call on the internet, go to the company&#x2019;s website at www.omeros.com and select &#x201C;Events&#x201D; under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">About Omeros Corporation</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">Omeros&nbsp;is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial drug OMIDRIA</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros&nbsp;has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros&#x2019; proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the &#x201C;safe harbor&#x201D; created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;could,&#x201D; &#x201C;estimate,&#x201D; &#x201C;expect,&#x201D; &#x201C;goal,&#x201D; &#x201C;intend,&#x201D; &#x201C;likely,&#x201D; &#x201C;look forward to,&#x201D; &#x201C;may,&#x201D; &#x201C;objective,&#x201D; &#x201C;plan,&#x201D; &#x201C;potential,&#x201D; &#x201C;predict,&#x201D; &#x201C;project,&#x201D; &#x201C;should,&#x201D; &#x201C;slate,&#x201D; &#x201C;target,&#x201D; &#x201C;will,&#x201D; &#x201C;would&#x201D; and similar expressions and variations thereof. Forward-looking statements are based on management&#x2019;s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros&#x2019; actual results could differ </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading &#x201C;Risk Factors&#x201D; in the company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, &nbsp;2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Contact</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Jennifer Cook Williams</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Cook Williams Communications, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Investor and Media Relations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">360.668.3701</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">jennifer@cwcomm.org</font><font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">OMEROS CORPORATION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(In thousands, except share and per share data)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.00%;">
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Three&nbsp;Months&nbsp;Ended<br>December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Year&nbsp;Ended<br>December 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Revenues:</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Product sales, net</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,417
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,017
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111,805
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,868
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Cost of product sales</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>401
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>157
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>865
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;padding-right:1.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>512
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,588
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,446
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109,696
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;padding-right:1.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,860
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Selling, general and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,132
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,888
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,626
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,718
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 34.55pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,121
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,491
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>175,187
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>142,090
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,704)
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18,474)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(63,382)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(112,222)
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Loss on early extinguishment of debt</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,993)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,993)
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Interest expense</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,811)
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,149)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,657)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,252)
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>290
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,553
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,781
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,225)
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,463)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(84,486)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(139,686)
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Income tax benefit</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,929
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,929
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,225)
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,534)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(84,486)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(126,757)
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.58)
				</td>
				<td valign="bottom" style="width:02.18%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.48)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.71)
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.61)
				</td>
				<td valign="bottom" style="width:00.50%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.34%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Weighted-average shares used to compute basic</font></p>
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50,622,516
				</td>
				<td valign="bottom" style="width:02.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,029,195
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49,523,444
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.58%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,582,636
				</td>
				<td valign="bottom" style="width:00.50%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">OMEROS CORPORATION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNAUDITED CONSOLIDATED BALANCE SHEET DATA</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(In thousands)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.38%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December 31,<br>2019</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,<br>2018</font></p>
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Cash, cash equivalents and short-term investments</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,788
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="middle" style="width:08.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,498
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Working capital</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,286
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,511
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Restricted investments</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,154
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,154
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136,969
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,936
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,459
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,356
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Lease liability</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,822
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,467
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Unsecured convertible senior notes, net</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,213
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,981
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(734,611)
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(650,125)
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total shareholders&#x2019; deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(109,021)
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(100,156)
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH K7]Y'I]A-=R_<B4MCU]!^)KG?!NLRWZW5O<ONF#F92?[K'D?@
M?YU4\=ZEDP:9&W_367'_ (Z/YG\JQ=,O?[!GLI_XYR))QZ0G@#\>6_!:\7$8
MUQQ:2?NQW^?]?F>O0P?-A6VO>EM\CU"BD!#*&4@@C((I:]H\@**** "BBB@
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M:N%52DO3\3*=%P@TOYOP'?&.Q>Y\&QW**3]DND=\=E(*Y_,BM#X926]]\/\
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MV.G^'VG2:7X%TNWE4K*T9E<'J"Y+?R(KD?B_X6LGTH^(H$6*[B=4GP,"92<
MG_:!QSZ?A7JG0<5YE<V^J?$Z9K:66'3M#M+DK+'&Q>:9E)'4@ #KC^M9TI2]
MI[3IU-:\(^R5+=]#J? -]<ZCX&TJYNV9YC$5+MU8*Q4$_@!16[9VD%A90V=K
7&(X($$<:#L ,"BL)-.3:.F"<8I,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>omer-20200302.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2020 9:10:41 PM-->
<!--Modified on: 3/2/2020 9:10:41 PM-->
<xsd:schema targetNamespace="http://www.omeros.com/20200302" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:omer="http://www.omeros.com/20200302">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="omer-20200302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="omer-20200302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="omer_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>omer-20200302_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2020 9:10:41 PM-->
<!--Modified on: 3/2/2020 9:10:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="omer-20200302.xsd#omer_DocumentAndEntityInformationAbstract" xlink:label="omer_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="omer_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="omer_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>omer-20200302_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.7293.39921 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2020 9:10:41 PM-->
<!--Modified on: 3/2/2020 9:10:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="omer-20200302.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="omer-20200302.xsd#omer_DocumentAndEntityInformationAbstract" xlink:label="omer_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637187802415553448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637187802415553448" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637187802415553448" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637187802415553448" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637187802415553448" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637187802415553448" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637187802415553448" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637187802415553448" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637187802415553448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637187802415553448" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637187802415563448" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637187802415563448" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637187802415563448" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637187802415563448" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637187802415563448" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637187802415563448" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637187802415563448" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637187802415563448" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637187802415563448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637187802415563448" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637187802415573448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637187802415573448" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637187802415573448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637187802415573448" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637187802415573448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637187802415573448" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637187802415573448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637187802415573448" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6622194864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OMEROS CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001285819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1663741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 Elliott Avenue West<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">omer_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>omer_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>omer-20200302x8kbf733aa_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="omer-20200302.xsd" xlink:type="simple"/>
    <context id="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001285819</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_idTC6a8o90Gq0KOQiBbASA_2_1">0001285819</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_ZndKK9OOu06C-qLVcWgQjg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_XqELUp-uWkO0PMKgbGSOqQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_OOQQPSpHsEK7l5Kt6WltyQ">2020-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_u8laeVwiukyafDAUDwlJHg">OMEROS CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_F9Fk0Q0AwkS2WJAjtU4zwA_0_0">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_zuV9QnQJRk-oCQea20Om0w_0_1">001-34475</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_1Nkl5EqvIECtuJgEckbm6w_0_2">91-1663741</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_X9A5RlJEFEumFiHP74irEg">201 Elliott Avenue West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_yFPrEcQGB0qeo_j3yVf1fQ">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_ClpitDxRl0G0RZ_yF19oig">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_nfV4K-gFWE6KWDt9OyqUvQ_3_2">98119</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_g3U0AO9cekSyd8GjtTEf0A">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_GvgO6AlSdU2gOmyXw64f0w">676-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_qCbkWREyI0mSMtvTW5ssuw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_LV9-E1N6GEyRNK0RI14wJw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_XqOFZg5EG0ikHG3G3H3Xlg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_x_t0pYSpR0GfcDsyZWdzKQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_G6B-50qyA0CTT1drdkKzog_1_0">Common stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_jv15teW0-UObMy9nhg1yYg_1_1">OMER</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Tc_KmonDcx4AkWaBHMm78UrLA_1_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ"
      id="Narr_zMvvgleXg0-oI5kyddtWIQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>11
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "omer-20200302x8kbf733aa.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "omer-20200302x8kbf733aa.htm"
     ]
    },
    "labelLink": {
     "local": [
      "omer-20200302_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "omer-20200302_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "omer-20200302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "omer",
   "nsuri": "http://www.omeros.com/20200302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "omer-20200302x8kbf733aa.htm",
      "contextRef": "Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.omeros.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "omer-20200302x8kbf733aa.htm",
      "contextRef": "Duration_3_2_2020_To_3_2_2020__2q6QZ5AeUSc43o1bYUHHQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "omer_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.omeros.com/20200302",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " !@@6)0M<7+D^X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/:L,P#(=?9?B>R$E8#B;-96.G%@8K;.QF;+4UB_]@:R1]^R5>
MFS*V!]C1TL^?/H$Z%83R$9^C#QC)8+J;[."24&'#3D1! "1U0BM3.2?<W#SX
M:"7-SWB$(-6'/"+4G+=@D:26)&$!%F$ELK[32JB(DGR\X+5:\>$S#AFF%>"
M%ATEJ,H*6+],#.=IZ. &6&"$T:;O NJ5F*M_8G,'V"4Y);.FQG$LQR;GYATJ
M>-MM7_*ZA7&)I%,X_TI&T#G@AETGOS8/C_LGUM>\Y@5O"E[OJU947-RW[XOK
M#[^;L/7:',P_-KX*]AW\NHO^"U!+ P04    " !@@6)0F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( &"!8E#MCSWXH@(  )@+   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL=5;MCILP$'P5Q ,<V)!/)4C-554KM5)T5:^_G<0)Z !3VPG7
MMZ]M.(J\ZS]@FYD=FV66W?5"OJF2<QV]-W6K]G&I=;=-$G4N></4D^AX:YY<
MA6R8-E-Y2U0G.;LX4E,G-$V72<.J-BYV;NTHBYVXZ[IJ^5%&ZMXT3/X]\%KT
M^YC$'PLOU:W4=B$I=AV[\9]<_^J.TLR2*<JE:GBK*M%&DE_W\2>R/=#<$ASB
MM>*]FHTC>Y23$&]V\NVRCU.[(U[SL[8AF+D]^#.O:QO)[.//&#2>-"UQ/OZ(
M_L4=WASFQ!1_%O7OZJ++?;R.HPN_LGNM7T3_E8\'6L31>/KO_,%K [<[,1IG
M42MWC<YWI44S1C%;:=C[<*]:=^^')WD^TG "'0GT/\'I)(.0V_EGIEFQDZ*/
MY/#R.V9S3+;4O)NS772OPCTSFU=F]5&DN^1APXR(PX"@,P29$(F)/0E05( Z
M>C:C4YR>H?3,T?,9/?/V!Q$Y+I"C CF@+SP!B%CB @M48 'H*T\ (M:XP!(5
M6 +ZQA. ")+B"BM4807YQ)- (($\KU&)->3[B48@@4QO4(D-Y/NI1B"!7),4
MMU,*(_CIQC"!A). :0F,X.<<P=! T@GN7$)A!#_M"":4=X(;G$#_4NJK()@L
MH(*[G$ 3T]Q703"+@ IN=0*=3)>^"H)9!51POQ-H9[KV51#,)J"">YY 1V?@
MUP Q017<]@2:.@/?&,0$57#G$^CK#'QC$!-2H;CW*?1UYM<P#!,H8A3W/H6^
MSOPRAF$"=8P&_MK0UYE?QS!,H(Y1W/L4^;O[=0S!!/.">Y]"7^?^EXQ@@$HR
MZZELS_J#R5O5JN@DM&G/7!-U%4)S$R]],BXO39L\36I^U7:X,F,Y](K#1(MN
M[(.3J1DO_@%02P,$%     @ 8(%B4#)<U7)5 @  !P8  !0   !X;"]S:&%R
M9613=')I;F=S+GAM;(5576_:0!!\3G_%"O6AE2#^"#BD(D@6(15*P!0C16K5
MA\->\*GVG7MW)O#ONX9^2#[<O&%N=W9F9\X>:6V@$OQGA1-9"7/?Z7L=.!2Y
MT/>=S)CRD^/H),."Z6M9HJ"3K50%,_2H=HXN%;)49XBFR!W?=0.G8%QTQB/-
MQR,S?I!)5: PP$0*4V&X.<),G!&X%"/'C$=.77HNGS-U#:[?!=_UW>;A&UCP
M+=QHHUABOK=VKH\E-@^'O:?6^B4J+NMA*3PP8[6>Z/K==U=7E_C^IKC"':]Y
M$=R"%19&-)^NHA@FT6H9K<+U+%JTX$R(D&(Y24[Q $]X;-:YKNOYP\'0NVM!
MF(E$JE*JT[JZ$!N2!%+!R7A%$V1JT7L)6\ >>8ZPJ(H-*IN(U[OI]V\'+:UK
M=H!92G+XEB=G[RX#W7D]+PAN;OM>"U*8I@JU[O[Y <]<($3"DN&['DSSG$MC
M(-RCJ!!>4)NW8"?U$VUH+5^MK,;(C,FM24V(OUM>*KGG(GFS82FU(9N_\O*B
M(7=#SS;XQ#.DJWBQQ7>#YE_/,J$9RTR*-A.#VZ WH$A9@5#<&!0TJ"CHO7'V
M3S>KMBS7%H]8YCSAAHL=S&DIBK.\6;)4V$L(&6E1YQN+%'<%T79K4[2*9UI7
M5/R_GC4GST!NP?,_;#Y"C$E%@JR[5*NC6&HCDQ]=>.]>4WY*IF#/<HI.2>@Z
M8\I2N%8LK>7%QV(C+7'U5;=3="8 TT.2,;'#BR^)11@_A%]:DC,M4.WJJ9^5
M?#59[4S)A"4II!6EIS4]YFSW[]2A+\#X%U!+ P04    " !@@6)0NJ$YBM<!
M   R!@  #0   'AL+W-T>6QE<RYX;6S555N+U3 0_BLA/\"<=MD%I2WHPH*@
MLK#GP=>TG;:!W$RGQW9_O4G3V]$'\>"#OC0SWTR^^7*9-.MQDO#2 2 9E=1]
M3CM$^XZQONI \?Z-L:!]I#%.<?2N:UEO'?"Z#Y.49.GI], 4%YH6F1[4D\*>
M5&;0F-,39476&+TC=S0"/I4K(!<N<_K(I2B=F'.Y$G**<!J RDCC"'HID-,D
M(/UK#"?1"RH7'B6T<0%DL4+\EDOZ3X'5Z[TKI-P$IC0"168Y(CC]Y)TY>09_
M"9'%/D_6*VP=GY+TGNX3YL$7*8VKP6UE$KI"12:A"7*<:+LPHK$L!!&-\D8M
M>&LTGS6L,Q;#TU8@Y4LXPJ_-%??8D)CSL0['0(**U?2K7LQX7-$)_$>VR'V@
MO;^)EEAQ,?AA\*O1L_]M, C/#AHQSO[8;/4].[=63N^E:+6"N);?%DQN+%AD
M?*U#.N/$J^<+-Z7R #A*+N!05$?DN^/V#".NMVEL;M6<_H>:__8^MZ#!<7D4
M[:_^O[S+?Z*8+=US:-&K!MU04@Y"HM"+QD[4-41YX87,Z9?P\,JK/MG[U-,C
M+_T#?L7OY];0\$'B<UCQ',SI;G\*+TWRL&6=-XJ<[O9GJ,6@WLX%][]$\0-0
M2P,$%     @ 8(%B4!9M(W]# 0  / (   \   !X;"]W;W)K8F]O:RYX;6R-
M4<MNPC 0_!7+'] $U"(5$2ZE#Z2J1:7B[B0;LL*/R-Y R]=W[2B%WGJR=W8\
M.SM>G)P_E,X=Q)?1-A2R)>KF61:J%HP*-ZX#RYW&>:.(2[_/0N=!U:$%(*.S
M:9[/,J/0RN5BU-KX[+IP!!6ALPQ&8(=P"I=^+(5BPA$^55G(7 K5DWM"3>!7
MBN#9N[Y#NR_D1(H&?:!MG)V8!BT:/$.=JM"ZTXOS>':6E-Y6WFF=7L5&>L03
MPB^R T]8_2&2*C\4>RWD+&?!(P8L42-]%S+=-4C>(KM:(^4PGD.(<_^?&%W3
M8 4K5_4&+ TY>M!QN@TM=D$*JPP4<J0(96OQ:(G=B+4=I)@;=^'1ZWK8BSBQ
MBUGAY\@-OZXGR?CHMH8&+=1O/" PSB%4&R_BD72FMW>3>PZ[U_J!L7?[ZE32
MCQKCQRU_ %!+ P04    " !@@6)0_\ F"+T   "% @  &@   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QSK9)!"H,P$ "_(GE 5VWIH:BG7KRV_4#0U8B:
MA.R6ZN^;>E%!H0<O"6'#S$"2/+"3W!A-JK$4#'VG*16*V=X J%#82SH9B]I/
M*N-ZR?[H:K"R:&6-$(?A%=R2(;)DR0SR,A4N+R,1O*2KD5,!0P<?XUI2B$PP
M;=')"_R5T>(_>E-538%W4[Q[U+Q1,0L$; ?%<Q IZ;!\LFMT34>'K.![,>=%
M#(\='E\Q4??TEUG/7H(PK8>_R43]-<#JUV5?4$L#!!0    ( &"!8E +C]@#
M(0$  %<$   3    6T-O;G1E;G1?5'EP97-=+GAM;+5434_#, S]*U.O:,W@
MP %MNP!7F 1_("1N&S5?LKW1_7O<;D-B*F)HVR6)\^SW7A(K\_=M!IITP4=:
M% US?E"*3 -!4YDR1$&JA$&SA%BKK$VK:U!WL]F],BDR1)YRSU$LYT]0Z;7G
MR>-NOZ=>%#IG[XQFEZ+:1'M$.MT3E@A^R*'&9;J1A&+RW D+R=ZB$)0*=8+"
M<6$?2]WK!A"=A7]92U7E#-ADUD%*2LH(VE(#P,&7U&@$^\;H8KWWN]+(+SH(
ML>J\^I%07L\';SV,&QB02RJSM 6,20W ;KP]2_#0#28A3#,*BNQ&CB>65H*2
MZA,O>43H6\>"/4E<J*_WL)\)VV$]=N'?(*EA.N_6_VATF<N@7?S-R$=*[4%?
M#?_)\@M02P$"% ,4    " !@@6)0'R// \     3 @  "P
M@ $     7W)E;',O+G)E;'-02P$"% ,4    " !@@6)0)^B'#H(   "Q
M$               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M &"!8E"UQ<N3[@   "L"   1              "  9D!  !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( &"!8E"97)PC$ 8  )PG   3
M  "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 8(%B4.V/
M/?BB @  F L  !@              ( !]P@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( &"!8E R7-5R50(   <&   4
M  "  <\+  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( &"!8E"Z
MH3F*UP$  #(&   -              "  58.  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ 8(%B4!9M(W]# 0  / (   \              ( !6!   'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &"!8E#_P"8(O0   (4"   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( &"!8E +C]@#(0$  %<$   3              "  ;T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="omer-20200302x8kbf733aa.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="omer-20200302x8kbf733aa.htm">omer-20200302x8kbf733aa.htm</File>
    <File>ex-99d1.htm</File>
    <File>omer-20200302.xsd</File>
    <File>omer-20200302_lab.xml</File>
    <File>omer-20200302_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001558370-20-001887-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-001887-xbrl.zip
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M*QE>8NP(6R6O5DTD/4X7V?S(CJG-M$,7L3X96DR1?J (L$]E< 2"D QEG-:
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M#N8<==H>,E$Q48\+506@J?%F3"4B(8R<X*=^I%1XJ*R63<FJJ!%-J9U)I ^
MNH+S(N .G;UN#)R92C66XG'A'=U2'*/F"A^OEI/1$SJ*<A=9C@?4SB!5=AE
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MJ7'94 8^CY-__/P#J^0<K9)W;[]0:%2A[3, [-N-GM5PGB$)F,O>5;C?9!,
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MKUXN(U^Q7S%8A\*"H3JHE<==X-X8H$(*T35QVLHH;!/  $H!Q12GP8]V2L%
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MOG(6O\UV5X>5Z<8 &3;VO(=F@!555 M_,@DIYJG%T!!L>Q\?G$(OB,7\'TS
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M9N3CBL?07/-A\H'X[@[+KM@VM^DZ@5@"7 5>A@073$THTJ>>91.3?Y8_<=Z
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MP!_=M4IQKS")OUAR6(AJIP*GZ%;")K)P = X3Z8^=GC09][,VHR!3A#H\OR
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M  ",= ( "P              @ $     97@M.3ED,2YH=&U02P$"% ,4
M" !@@6)0F/PW=K #  #+#   $0              @ %V+P  ;VUE<BTR,#(P
M,#,P,BYX<V102P$"% ,4    " !@@6)004SY1HD%  #5/   %0
M    @ %5,P  ;VUE<BTR,#(P,#,P,E]L86(N>&UL4$L! A0#%     @ 8(%B
M4 4EJ4N+!   52D  !4              ( !$3D  &]M97(M,C R,# S,#)?
M<')E+GAM;%!+ 0(4 Q0    ( &"!8E"D4UB%<A,  #F    ;
M  "  <\]  !O;65R+3(P,C P,S R>#AK8F8W,S-A82YH=&U02P4&      4
,!0!' 0  >E$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
